

**DANSK PROTOKOLTILLÆG TIL**

Handling oxygenation targets in adults with acute hypoxaemic respiratory failure in the intensive care unit:

A randomised clinical trial of a lower versus a higher oxygenation target (HOT-ICU)


EudraCT number: 2017-000632-34

ClinicalTrials.gov Identifier (HOT-ICU): NCT03174002

ClinicalTrials.gov Identifier (HOT-COVID tillægsstudie): NCT04425031

Videnskabsetisk Komité: N-20170015

14/8 - 2020



Professor, overlæge, ph.d.  
**Bodil Steen Rasmussen**  
Anæstesi og Intensiv Afdeling  
Aalborg Universitetshospital

Corresponding author, sponsor and primary investigator of the HOT-ICU trial:

Bodil Steen Rasmussen

Professor, chief consultant, PhD

Department of Anaesthesia and Intensive Care

Aalborg University Hospital

Hobrovej 18-22

9100 Aalborg

Denmark

## Introduction

On March 12<sup>th</sup> 2020, the World Health Organisation declared coronavirus disease 2019 (COVID-19) a global pandemic.<sup>1</sup> On May 28<sup>th</sup> 2020, more than 5.6 million infected people and 353.334 deaths have been reported globally with many more anticipated.<sup>2</sup> There are no specific therapies for infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and supportive care is the mainstay in the management of these patients.<sup>3</sup> Acute hypoxaemic respiratory failure is the hallmark of hospitalised patients with COVID-19 and the main key factor contributing to a fatal outcome.<sup>4,5</sup> In these patients supplementary oxygen is the most commonly prescribed therapy.<sup>6</sup>

COVID-19 patients acutely admitted to the intensive care unit (ICU) for mechanical ventilation and oxygen therapy fulfil the criteria of acute respiratory distress syndrome (ARDS).<sup>7</sup> In ARDS, the mortality rate is 35-46% depending on severity,<sup>8</sup> however, in COVID-19 patients the mortality rate may be doubled.<sup>4,5,9</sup>

COVID-19 patients acutely admitted to the ICU are eligible in the ongoing multicentre trial, Handling Oxygenation Targets in the Intensive Care Unit (HOT-ICU), and since March 2020 a total of 92 COVID-19 patients have been included out of the 2.799 patients randomised so far (see Figure 1). With the expected completion of the HOT-ICU trial in June/July 2020, the number of COVID-19 patients will be too small to draw any conclusions regarding the optimal oxygenation target in this subgroup of ARDS patients.

Due to lack of evidence, the current oxygenation targets in ARDS patients often follows the regimen used in both the conventional and the interventional group in a randomised clinical trial (RCT) published in 2000 aiming to compare higher versus lower tidal volumes; i.e. a partial pressure of arterial oxygen ( $\text{PaO}_2$ ) of 55-80 mmHg (7.3-10.7 kPa) or a peripheral oxygen saturation ( $\text{SpO}_2$ ) of 88-95%.<sup>10</sup> A recently published RCT challenges this postulate as the trial was prematurely stopped due to five cases of intestinal ischaemia, when targeting a lower oxygenation ( $\text{PaO}_2$ : 7.3-9.3 kPa) compared to none, when targeting a higher oxygenation ( $\text{PaO}_2$ : 12.0-14.0 kPa).<sup>11</sup> Importantly, myocardial and intestinal ischemia as well as ischaemic stroke are all secondary outcomes in the HOT-ICU trial and were evaluated by the Data Monitoring and Safety Committee (DMSC) at the planned interim analysis, when 1464 patients had passed their 90-day follow-up. We aim to extend the HOT-ICU trial to focus exclusively on COVID-19 patients, being characterised by a specific aetiology and a common presentation, in the HOT-COVID trial.

## Aim

To assess benefits and harms of two targets of  $\text{PaO}_2$  in guiding medical oxygen administration in SARS-CoV-2 positive patients acutely admitted to the intensive care unit (ICU) with hypoxaemic respiratory failure.

## Methods

### *Study population*

This is an amendment to the HOT-ICU trial exclusively for SARS-CoV-2 positive patients. The main HOT-ICU protocol applies to all patients included in the extended HOT-COVID trial, the only protocol alterations are those described here. The presence of a positive test for SARS-CoV-2 in any airway secretion or naso-pharyngeal swab prior to the inclusion in the trial is added to the inclusion criteria. Additionally, the fraction of inspired oxygen (FiO<sub>2</sub>) criterion for mechanically ventilated patients will be removed, as all mechanically ventilated COVID-19 patients have hypoxaemic respiratory failure.

### *Inclusion criteria (unchanged is marked in italics)*

- *Acutely admitted to the ICU* **AND**
- *Aged ≥ 18 years* **AND**
- *Supplemental oxygen with a flow of at least 10 L oxygen per minutes in an open system including high-flow systems OR invasive or non-invasive mechanical ventilation/CPAP systems independent of the FiO<sub>2</sub>* **AND**
- *Expected to receive supplemental oxygen for at least 24 hours in the ICU* **AND**
- *Having an arterial line for PaO<sub>2</sub> monitoring* **AND**
- Confirmed SARS-CoV-2 infection in the time leading to or during current hospital admission

### *Exclusion*

- All exclusion criteria are similar to those specified in the HOT-ICU trial

### *Outcomes*

By changing the primary outcome parameter from 90-days mortality to days alive without life support, the HOT-COVID will be more feasible as a lower number of patients is needed to demonstrate a clinically relevant difference. Importantly, all outcomes are similar to those specified in the HOT-ICU trial.

### *Primary outcome*

- Days alive without life support, i.e. respiratory support, circulatory support or renal replacement therapy (RRT) in 90 days after randomisation (*secondary outcome in main HOT-ICU trial*)

### *Secondary outcomes*

- 90-day mortality (*primary outcome in the main HOT-ICU trial*)
- All other secondary outcomes are similar to those specified in the HOT-ICU trial

### *Power sample calculation*

Given the current knowledge 40% of ICU admitted coronavirus disease 2019 (COVID-19) patients will die while on life support and will thus have 0 days alive and out of life support. Surviving patients will have estimated 14 days receiving life support out of the 90 days. Therefore, with an average of 45.6 days alive without life support and a standard deviation of 35.0 days, to achieve a maximal type 1 error of 5% and type 2 error of 20% (a power of 80%), a total of 780 patients will be included in the HOT-COVID trial to detect or reject a true absolute increase of 7.0 days in days alive without life support, equal to a 20% mortality reduction (an absolute mortality reduction of 8%-points) and a 10% decrease in days receiving life support in survivors (an absolute decrease of 1.4 days); i.e. estimated 52.6 days alive without life support in the intervention group.

A detailed statistical analysis plan will be published before inclusion of the last patient in the HOT-COVID trial.

#### *Interim analysis*

We will conduct one interim analysis when 390 COVID-19 patients (50%) have been followed for 90 days. A blinded DMSC will analyse the primary outcome, the 90-day mortality, and the serious adverse events (SAE) outcome. The DMSC will submit their recommendations to the HOT-ICU Management Committee, which makes the final decision regarding the continuing, pausing or stopping of the trial as described in the charter for the independent DMSC of the HOT-ICU trial.

### **Co-enrolment**

#### *General considerations*

Critically ill patients in the ICU are treated with many different therapies in addition to the trial intervention due to acute and chronic illnesses. Therefore, the potential for interactions is a prerequisite meaning that co-enrolments may not differ from what occurs in single-enrolment trials (12). In pragmatic trials, like the HOT-COVID trial, other interventions will be given at random and if interaction is an issue, it may be better controlled for if patients are co-enrolled and randomised to more than one intervention.

More high-quality clinical research can be conducted in a timely fashion and more information can be generated to guide clinical practice, if co-enrolment is permitted (13).

#### *Ethical considerations*

Preventing eligible patients from co-enrolment in clinical trials contravenes a fundamental principle of research ethics (12). Permitting co-enrolment is in accordance with existing recommendations for the conduct of trustworthy clinical practice guidelines, taking into account benefits and harms, quality of



evidence, values and preferences of patients or their proxies and cost considerations, as outlined by the Institute of Medicine, the Guideline International Network, and according to The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology (14-16). Patient relatives have limited concerns about co-enrolment (17).

#### *Scientific and statistical considerations*

Pragmatic clinical trials allowing inclusion of a broad range of trial participants with different medicines and other therapies have higher external validity/generalisability than nonpragmatic trials with restrictions regarding trial participants and co-enrolment (18). Co-enrolment in pragmatic trials facilitates evaluation of clinically relevant and patient important interactions (12). Co-enrolment into two or more trials does not invalidate the original randomisation of the individual trials and separate analysis of each individual trial, ignoring the issue of co-enrolment into the other trial, will retain the balance of patient characteristics expected by standard random assignment within each trial (12). Co-enrolment into two or more trials does not seem to affect the natural course of the disease of the other condition being studied (12). Co-enrolment does not appear to influence patient safety or trial results (19,20). Empirically, co-enrolment has a small effect on study power (12). The National Institute of Health supports co-enrolment (18); so does the Canadian Critical Care Trials group (<http://www.ccctg.ca/Home.aspx>) and the Australian New Zealand Intensive Care Society's Clinical Trial Group (<http://www.anzics.com.au/Pages/CTG/CTG-home.aspx>).

We do not expect imbalance in group allocations and even if an imbalance should occur, the number of co-enrolled participants will be small and the intervention effects for both trials (HOT-COVID and where co-enrolled) will be small, thus the probability that the result of one trial will affect the other trial is very low. In conclusion, the HOT-COVID Management Committee endorses and encourages co-enrolment because of an overall benefit, including ethical, practical and scientific benefit, and no evidence of harm.

#### *Co-enrolment agreement*

A co-enrolment form will be filled in (Appendix 1) for a trial to be evaluated as counterpart for co-enrolment with HOT-COVID, and send by e-mail to [hot-covid@cric.nu](mailto:hot-covid@cric.nu). Thereafter, the sponsor of the trial will be contacted to facilitate exchange of protocols and other relevant documents between the Steering Committees. A list of titles already accepted for co-enrolment in the HOT-ICU trial can be found by clicking <http://www.cric.nu/hot-icu-co-enrolment-list/>

### **Time schedule**

The HOT-COVID trial will start as soon as the last patient in the main HOT-ICU trial has been included, which is expected to be in June/July 2020. The inclusion period of the HOT-COVID trial is expected to be completed in two years.

Participating sites in the HOT-ICU trial have been invited to continue their participation. Prolongation of contracts and approvals by the authorities will be obtained.

### **Risks, side effects and disadvantages, and guidelines for oral information and informed consent**

The same as in the main HOT-ICU trial as there is no new evidence regarding the two oxygenation targets of a  $\text{PaO}_2$  of 8 kPa and a  $\text{PaO}_2$  of 12 kPa, respectively, and the regulations regarding informed consent in temporarily incompetent patients have not changed either.

### **Economy**

The primary investigator of the HOT-ICU trial and of the extension HOT-COVID trial, Professor Bodil Steen Rasmussen, Department of Anaesthesia and Intensive Care, Aalborg University Hospital, has initiated the trials. Funding to run the HOT-COVID trial has been granted by the Ministry of Higher Education and Research: 5 mill DDK. None of the researchers involved have financial interests in the trial.

### **Ethics**

The study will provide new important information of the effects of different targets of oxygenation in critically ill SARS-CoV-2 positive patients acutely admitted to the ICU with hypoxaemic respiratory failure.

### **Publishing of results**

All results of the project will be published regardless of the outcomes.

### **References**

1. [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200528-covid-19-sitrep-129.pdf?sfvrsn=5b154880\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200528-covid-19-sitrep-129.pdf?sfvrsn=5b154880_2)
2. [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200524-covid-19-sitrep-125.pdf?sfvrsn=80e7d7f0\\_2](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200524-covid-19-sitrep-125.pdf?sfvrsn=80e7d7f0_2)
3. Murthy S, Gomersall CD, Fowler RA (2020) Care for Critically Ill Patients With COVID-19. JAMA 2020;323:1499-1500
4. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York Area. JAMA 2020;323:2052-2059

5. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs in the Lombardy Region, Italy. *JAMA* 2020;323:1574-1581
6. Wang D, Hu B, Hu C, et al (2020) Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020;323:1061-1069
7. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. *JAMA*. 2012;307:2526-2533
8. Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 Countries. *JAMA* 2016;315:788-800
9. <https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports>
10. Brower RB, Matthay MA, Morris A, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000; 342: 1301-1308
11. Barrot L, Asfar P, Mauny F, et al. Liberal or conservative oxygen therapy for acute respiratory distress syndrome. *N Engl J Med* 2020;382:999-1008
12. Myles PS, Williamson E, Oakley J, Forbes A. Ethical and scientific considerations for patient enrollment into concurrent clinical trials. *Trials* 2014;15:470
13. Faden RR, Beauchamp TL, Kass NE. Informed consent, comparative effectiveness, and learning health care. *N Engl J Med* 2014;370:766-768
14. Faden RR, Beauchamp TL, Kass NE. Informed consent, comparative effectiveness, and learning health care. *N Engl J Med* 2014;370:766-768
15. Faden RR, Beauchamp TL, Kass NE. Informed consent, comparative effectiveness, and learning health care. *N Engl J Med* 2014;370:766-768
16. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924-926
17. Burgess E, Singhal N, Amin H, et al. Consent for clinical research in the neonatal intensive care unit: a retrospective survey and a prospective study. *Arch Dis Child Fetal Neonatal Ed* 2003;88:F280-F285; discussion F5-6
18. Randolph AG. The unique challenges of enrolling patients into multiple clinical trials. *Crit Care Med* 2009;37:S107-S111
19. Cook D, McDonald E, Smith O, I, et al. Co-enrollment of critically ill patients into multiple studies: patterns, predictors and consequences. *Crit Care* 2013;17:R1
20. Cook DJ, Ferguson ND, Hand L, et al. Coenrollment in a randomized trial of high-frequency oscillation: prevalence, patterns, predictors, and outcomes. *Crit Care Med* 2015;43:328-338

Figure 1. Overview of HOT-ICU recruitment

27 July 2020

